Tenon Medical (TNON) Maxim Group’s 2024 Healthcare Virtual Summit summary

Conference overview

• The event was the second day of a three-day virtual healthcare conference, featuring presentations and Q&A with medical device innovators.

• The presenting company is focused on sacroiliac (SI) joint solutions, with nearly 800 procedures completed and a buy rating with a $4 twelve-month price target.

Technology and clinical progress

• The company developed a minimally invasive implant for SI joint fusion, addressing pain and instability, especially in postpartum women and those unresponsive to conservative care.

• Interim clinical research shows statistically significant pain reduction and successful bone fusion at 12 months, with strong safety data.

• The implant uses autologous bone grafts, leveraging the patient's own bone for optimal healing, and employs a unique inferior-posterior approach.

Market differentiation and competitive landscape

• Earlier SI joint solutions used lateral approaches and multiple implants, but the current technology preps the joint for healing and uses a single implant to immobilize and facilitate fusion.

• The company claims a safer, more effective approach compared to competitors, with ongoing clinical research expected to reinforce these advantages.